Cart
sales@molnova.com
Dexketoprofen trometamol
CAS No. 156604-79-4
Dexketoprofen trometamol( —— )
Catalog No. M23677 CAS No. 156604-79-4
Dexketoprofen trometamol is a modified non-selective COX inhibitor with a rapid onset of action that is available as both oral and parenteral formulations.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 51 | In Stock |
|
| 10MG | 74 | In Stock |
|
| 25MG | 135 | In Stock |
|
| 50MG | 192 | In Stock |
|
| 100MG | 275 | In Stock |
|
| 200MG | 394 | In Stock |
|
| 500MG | 591 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameDexketoprofen trometamol
-
NoteResearch use only, not for human use.
-
Brief DescriptionDexketoprofen trometamol is a modified non-selective COX inhibitor with a rapid onset of action that is available as both oral and parenteral formulations.
-
DescriptionDexketoprofen trometamol is a modified non-selective COX inhibitor with a rapid onset of action that is available as both oral and parenteral formulations.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayChromatin/Epigenetic
-
TargetCOX
-
RecptorCOX-2
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number156604-79-4
-
Formula Weight375.42
-
Molecular FormulaC20H25NO6
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (266.37 mM)
-
SMILESO=C(C1=CC=CC([C@H](C)C(O)=O)=C1)C2=CC=CC=C2.OCC(CO)(CO)N
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Hanna M , Moon J Y . A review of dexketoprofen trometamol in acute pain[J]. Current Medical Research and Opinion, 2018:1-32.
molnova catalog
related products
-
Loxoprofen sodium
Loxoprofen sodium (CS-600) is an effective and oral sodium inhibitor of COX-1 and COX-2 with IC50 of 6.5 and 13.5 μM, respectively.
-
Tolfenamic Acid
Tolfenamic acid (TA) is one of the class of non-steroidal anti-inflammatory drugs (NSAIDs).
-
Pamicogrel
Pamicogrel is an inhibitor of COX. Pamicogrel has platelet anti-aggregatory properties which is under development by Kanebo for chronic arterial occlusion.
